Review



murine anti il6 neutralizing antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Bio X Cell murine anti il6 neutralizing antibody
    Gene expression and GSEA analysis of <t>IL6</t> in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts
    Murine Anti Il6 Neutralizing Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 136 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine anti il6 neutralizing antibody/product/Bio X Cell
    Average 96 stars, based on 136 article reviews
    murine anti il6 neutralizing antibody - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer"

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-024-03002-1

    Gene expression and GSEA analysis of IL6 in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts
    Figure Legend Snippet: Gene expression and GSEA analysis of IL6 in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts

    Techniques Used: Gene Expression, Expressing

    Blocking IL6 signaling induces the remission of HPV − tumors in orthotopic tumor mouse models. A IL6 concentration in the peripheral serum of C57BL/6 mice bearing MOC2 or TC-1 tumors. B Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype or αIL6 (100 µg/mouse) ( n = 5/group). C , D MOC2 tumor growth curve and weight in each treatment group. E , F TC-1 tumor growth curve and weight in each treatment group. In ( C ) and ( E ), representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel. * p < 0.05; ns: not significant
    Figure Legend Snippet: Blocking IL6 signaling induces the remission of HPV − tumors in orthotopic tumor mouse models. A IL6 concentration in the peripheral serum of C57BL/6 mice bearing MOC2 or TC-1 tumors. B Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype or αIL6 (100 µg/mouse) ( n = 5/group). C , D MOC2 tumor growth curve and weight in each treatment group. E , F TC-1 tumor growth curve and weight in each treatment group. In ( C ) and ( E ), representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel. * p < 0.05; ns: not significant

    Techniques Used: Blocking Assay, Concentration Assay, Injection

    Blocking IL6 signaling enhances the antitumor activity of NK cells in HPV − tumors. A , B Percent of CD8 + T cells and CD161 + NK cells in MOC2 tumors treated with isotype or αIL6. C Percent of Ki67 + NK cells in MOC2 tumors treated with isotype or αIL6. D , E Percent of CD8 + T cells and CD161 + NK cells in TC-1 tumors treated with isotype or αIL6. F Percent of Ki67 + NK cells in TC-1 tumors treated with isotype or αIL6. G Immunofluorescence staining of anti-CD161 antibody in MOC2 and TC-1 tumors treated with isotype or αIL6. Representative images and quantitative data are shown in the left and right panels. In ( A , B , D , E ), T cells and NK cells were gated from CD3 + and CD3 − population, respectively. * p < 0.05; ** p < 0.01; ns: not significant
    Figure Legend Snippet: Blocking IL6 signaling enhances the antitumor activity of NK cells in HPV − tumors. A , B Percent of CD8 + T cells and CD161 + NK cells in MOC2 tumors treated with isotype or αIL6. C Percent of Ki67 + NK cells in MOC2 tumors treated with isotype or αIL6. D , E Percent of CD8 + T cells and CD161 + NK cells in TC-1 tumors treated with isotype or αIL6. F Percent of Ki67 + NK cells in TC-1 tumors treated with isotype or αIL6. G Immunofluorescence staining of anti-CD161 antibody in MOC2 and TC-1 tumors treated with isotype or αIL6. Representative images and quantitative data are shown in the left and right panels. In ( A , B , D , E ), T cells and NK cells were gated from CD3 + and CD3 − population, respectively. * p < 0.05; ** p < 0.01; ns: not significant

    Techniques Used: Blocking Assay, Activity Assay, Immunofluorescence, Staining

    αIL6 and RS504393 promote NK cell antitumor activity and repress MOC2 tumors more effectively when combined. A , F Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype, αIL6 (100 µg/mouse), RS504393 (6 mg/kg) or the combination of αIL6 and RS504393 ( n = 5/group). B , C MOC2 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( B ). D , I Percent of CD161 + NK cells in MOC2 ( D ) or TC-1 ( I ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. E , K Percent of Ki67 + NK cells in MOC2 ( E ) or TC-1 ( K ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. G , H TC-1 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( G ). * p < 0.05; ** p < 0.01; ns: not significant
    Figure Legend Snippet: αIL6 and RS504393 promote NK cell antitumor activity and repress MOC2 tumors more effectively when combined. A , F Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype, αIL6 (100 µg/mouse), RS504393 (6 mg/kg) or the combination of αIL6 and RS504393 ( n = 5/group). B , C MOC2 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( B ). D , I Percent of CD161 + NK cells in MOC2 ( D ) or TC-1 ( I ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. E , K Percent of Ki67 + NK cells in MOC2 ( E ) or TC-1 ( K ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. G , H TC-1 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( G ). * p < 0.05; ** p < 0.01; ns: not significant

    Techniques Used: Activity Assay, Injection

    Depletion of NK cells attenuates the antitumor activity of the αIL6 and RS504393 combination in orthotopic mouse models. A Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of either 1.0 × 10 6 MOC2 or MOC1 cells. Tumor-bearing mice were randomized to receive the combination treatment of the αIL6 (100 µg/mouse) and RS504393 (6 mg/kg), in the presence of αASGM1 or rabbit polyclonal IgG isotype ( n = 10/group). B , C Individual and average MOC2 tumor growth curves. D , E Individual and average MOC1 tumor growth curves. F , G MOC2 and MOC1 tumor weight in each treatment group. * p < 0.05; ** p < 0.01; ns: not significant
    Figure Legend Snippet: Depletion of NK cells attenuates the antitumor activity of the αIL6 and RS504393 combination in orthotopic mouse models. A Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of either 1.0 × 10 6 MOC2 or MOC1 cells. Tumor-bearing mice were randomized to receive the combination treatment of the αIL6 (100 µg/mouse) and RS504393 (6 mg/kg), in the presence of αASGM1 or rabbit polyclonal IgG isotype ( n = 10/group). B , C Individual and average MOC2 tumor growth curves. D , E Individual and average MOC1 tumor growth curves. F , G MOC2 and MOC1 tumor weight in each treatment group. * p < 0.05; ** p < 0.01; ns: not significant

    Techniques Used: Activity Assay, Injection

    A proposed model for this study. A In the microenvironment of HPV − HNSCC, IL6/IL6R and CCL2/CCR2 signaling exert a significant influence on the ability of HPV − tumor cells to evade immune attacks by NK cells. B Simultaneous blockade of IL6/IL6R and CCL2/CCR2 with αIL6 and RS504393 is effective in enhancing the antitumor activity of NK cells in HPV − HNSCC
    Figure Legend Snippet: A proposed model for this study. A In the microenvironment of HPV − HNSCC, IL6/IL6R and CCL2/CCR2 signaling exert a significant influence on the ability of HPV − tumor cells to evade immune attacks by NK cells. B Simultaneous blockade of IL6/IL6R and CCL2/CCR2 with αIL6 and RS504393 is effective in enhancing the antitumor activity of NK cells in HPV − HNSCC

    Techniques Used: Activity Assay



    Similar Products

    murine anti il6 neutralizing antibody  (Bio X Cell)
    96
    Bio X Cell murine anti il6 neutralizing antibody
    Gene expression and GSEA analysis of <t>IL6</t> in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts
    Murine Anti Il6 Neutralizing Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine anti il6 neutralizing antibody/product/Bio X Cell
    Average 96 stars, based on 1 article reviews
    murine anti il6 neutralizing antibody - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Gene expression and GSEA analysis of IL6 in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: Gene expression and GSEA analysis of IL6 in TCGA HNSCC cohorts. A Differential analysis of IL6 expression between HPV − and HPV + HNSCC cohorts using TCGA dataset. B DEGs stratified by IL6 high and low expression in HPV − HNSCC cohort. C Expression correlation analysis between IL6 and the top nine upregulated DEGs identified in the IL6 high-expression group. D Pathway enrichment analysis (IL6 high expression vs IL6 low expression) revealing the ‘natural killer cell mediated cytotoxicity’ pathway in TCGA HPV − HNSCC cohort. E Correlation between the expression of IL6 and the other 4 DEGs upregulated in HPV − HNSCC cells vs HPV + HNSCC cells. F Correlation analysis of the gene expression between IL6 and CCR2 in TCGA HPV − HNSCC cohorts

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Gene Expression, Expressing

    Blocking IL6 signaling induces the remission of HPV − tumors in orthotopic tumor mouse models. A IL6 concentration in the peripheral serum of C57BL/6 mice bearing MOC2 or TC-1 tumors. B Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype or αIL6 (100 µg/mouse) ( n = 5/group). C , D MOC2 tumor growth curve and weight in each treatment group. E , F TC-1 tumor growth curve and weight in each treatment group. In ( C ) and ( E ), representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel. * p < 0.05; ns: not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: Blocking IL6 signaling induces the remission of HPV − tumors in orthotopic tumor mouse models. A IL6 concentration in the peripheral serum of C57BL/6 mice bearing MOC2 or TC-1 tumors. B Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype or αIL6 (100 µg/mouse) ( n = 5/group). C , D MOC2 tumor growth curve and weight in each treatment group. E , F TC-1 tumor growth curve and weight in each treatment group. In ( C ) and ( E ), representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel. * p < 0.05; ns: not significant

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Blocking Assay, Concentration Assay, Injection

    Blocking IL6 signaling enhances the antitumor activity of NK cells in HPV − tumors. A , B Percent of CD8 + T cells and CD161 + NK cells in MOC2 tumors treated with isotype or αIL6. C Percent of Ki67 + NK cells in MOC2 tumors treated with isotype or αIL6. D , E Percent of CD8 + T cells and CD161 + NK cells in TC-1 tumors treated with isotype or αIL6. F Percent of Ki67 + NK cells in TC-1 tumors treated with isotype or αIL6. G Immunofluorescence staining of anti-CD161 antibody in MOC2 and TC-1 tumors treated with isotype or αIL6. Representative images and quantitative data are shown in the left and right panels. In ( A , B , D , E ), T cells and NK cells were gated from CD3 + and CD3 − population, respectively. * p < 0.05; ** p < 0.01; ns: not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: Blocking IL6 signaling enhances the antitumor activity of NK cells in HPV − tumors. A , B Percent of CD8 + T cells and CD161 + NK cells in MOC2 tumors treated with isotype or αIL6. C Percent of Ki67 + NK cells in MOC2 tumors treated with isotype or αIL6. D , E Percent of CD8 + T cells and CD161 + NK cells in TC-1 tumors treated with isotype or αIL6. F Percent of Ki67 + NK cells in TC-1 tumors treated with isotype or αIL6. G Immunofluorescence staining of anti-CD161 antibody in MOC2 and TC-1 tumors treated with isotype or αIL6. Representative images and quantitative data are shown in the left and right panels. In ( A , B , D , E ), T cells and NK cells were gated from CD3 + and CD3 − population, respectively. * p < 0.05; ** p < 0.01; ns: not significant

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Blocking Assay, Activity Assay, Immunofluorescence, Staining

    αIL6 and RS504393 promote NK cell antitumor activity and repress MOC2 tumors more effectively when combined. A , F Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype, αIL6 (100 µg/mouse), RS504393 (6 mg/kg) or the combination of αIL6 and RS504393 ( n = 5/group). B , C MOC2 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( B ). D , I Percent of CD161 + NK cells in MOC2 ( D ) or TC-1 ( I ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. E , K Percent of Ki67 + NK cells in MOC2 ( E ) or TC-1 ( K ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. G , H TC-1 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( G ). * p < 0.05; ** p < 0.01; ns: not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: αIL6 and RS504393 promote NK cell antitumor activity and repress MOC2 tumors more effectively when combined. A , F Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10 6 MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype, αIL6 (100 µg/mouse), RS504393 (6 mg/kg) or the combination of αIL6 and RS504393 ( n = 5/group). B , C MOC2 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( B ). D , I Percent of CD161 + NK cells in MOC2 ( D ) or TC-1 ( I ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. E , K Percent of Ki67 + NK cells in MOC2 ( E ) or TC-1 ( K ) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. G , H TC-1 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of ( G ). * p < 0.05; ** p < 0.01; ns: not significant

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Activity Assay, Injection

    Depletion of NK cells attenuates the antitumor activity of the αIL6 and RS504393 combination in orthotopic mouse models. A Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of either 1.0 × 10 6 MOC2 or MOC1 cells. Tumor-bearing mice were randomized to receive the combination treatment of the αIL6 (100 µg/mouse) and RS504393 (6 mg/kg), in the presence of αASGM1 or rabbit polyclonal IgG isotype ( n = 10/group). B , C Individual and average MOC2 tumor growth curves. D , E Individual and average MOC1 tumor growth curves. F , G MOC2 and MOC1 tumor weight in each treatment group. * p < 0.05; ** p < 0.01; ns: not significant

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: Depletion of NK cells attenuates the antitumor activity of the αIL6 and RS504393 combination in orthotopic mouse models. A Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of either 1.0 × 10 6 MOC2 or MOC1 cells. Tumor-bearing mice were randomized to receive the combination treatment of the αIL6 (100 µg/mouse) and RS504393 (6 mg/kg), in the presence of αASGM1 or rabbit polyclonal IgG isotype ( n = 10/group). B , C Individual and average MOC2 tumor growth curves. D , E Individual and average MOC1 tumor growth curves. F , G MOC2 and MOC1 tumor weight in each treatment group. * p < 0.05; ** p < 0.01; ns: not significant

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Activity Assay, Injection

    A proposed model for this study. A In the microenvironment of HPV − HNSCC, IL6/IL6R and CCL2/CCR2 signaling exert a significant influence on the ability of HPV − tumor cells to evade immune attacks by NK cells. B Simultaneous blockade of IL6/IL6R and CCL2/CCR2 with αIL6 and RS504393 is effective in enhancing the antitumor activity of NK cells in HPV − HNSCC

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

    doi: 10.1186/s13046-024-03002-1

    Figure Lengend Snippet: A proposed model for this study. A In the microenvironment of HPV − HNSCC, IL6/IL6R and CCL2/CCR2 signaling exert a significant influence on the ability of HPV − tumor cells to evade immune attacks by NK cells. B Simultaneous blockade of IL6/IL6R and CCL2/CCR2 with αIL6 and RS504393 is effective in enhancing the antitumor activity of NK cells in HPV − HNSCC

    Article Snippet: Ten days after cell inoculation, tumor-bearing mice were randomized into two groups to receive murine anti-IL6 neutralizing antibody (αIL6, clone MP5-20F3, BioXCell) and IgG2 isotype.

    Techniques: Activity Assay